Patrick Y. Wen MD
Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Director, Division of Cancer Neurology, Department of Neurology, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School, Boston, MassachusettsBiographical Sketch:
Dr. Patrick Wen is Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and Director of the Division of Cancer Neurology in the Department of Neurology at Brigham and Women’s Hospital. He is Professor of Neurology at Harvard Medical School.
After receiving his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, Dr. Wen underwent residency training at Harvard Longwood Neurology Training Program, and completed his clinical and research fellowship in neurology at the Center for Neurologic Diseases, Brigham and Women's Hospital, in Boston, Massachusetts.
Dr. Wen is a former President of the Society for Neuro-Oncology (SNO). Dr. Wen is a fellow in the Royal College of Physicians, the Royal Society of Medicine, the American Academy of Neurology, and the American Neurological Association. He is also a member of a number of other professional organizations, including the British Medical Association, American Neurological Association, Society for Neuro-Oncology, and American Society of Clinical Oncology, among others. He sits on the editorial boards of various publications, was Editor-in-Chief of Neuro-Oncology, and is currently the SNO Executive Editor.
Dr. Wen’s research focuses on novel treatments for brain tumors and optimizing response assessment and clinical trial endpoints in neuro-oncology. He is a member of the steering committee of the Response Assessment in Neuro-Oncology (RANO) Working Group. He has published and presented his research widely.
Positions:
Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Director, Division of Cancer Neurology, Department of Neurology, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School, Boston, Massachusetts. Editor-in Chief, Neuro-Oncology.
Degrees:
MD: Medical College of St. Bartholomew's Hospital, University of London, England
Postgraduate Training:
Fellowship (neurology): Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts
Research Interests:
Novel treatments for brain tumors
Disclosures
Patrick Wen, MD, is a member of the Speaker’s Bureau for Merck and Prime Oncology.
Patrick Wen, MD, serves as a consultant/advisory board member for Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines.
Patrick Wen, MD, received research support from Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines.
Recent Contributions to PracticeUpdate:
- Oncolytic Viral Immunotherapy for High-Grade Glioma
- Nivolumab for Patients With MGMT Promoter Methylated Glioblastoma
- Serial MRD Assessment in Medulloblastoma Liquid Biopsies
- Integrated Molecular–Morphologic Meningioma Classification
- Primary Brain and Other CNS Tumors Diagnosed in the US in 2014–2018
- ESMO 2021: Recommendations From Dr. Patrick Wen for Central Nervous System Tumors
- Tryptophan Metabolism Drives Dynamic Immunosuppressive Myeloid States in IDH-Mutant Gliomas
- Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma
- NF1 Mutation Drives Neuronal Activity–Dependent Initiation of Optic Glioma
- ASCO 2021: Abstract Recommendations From Dr. Patrick Wen for Central Nervous System Tumors